MedTrace Logo

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

NCT03752398 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 198

Last updated 2024-07-05

No results posted yet for this study

Summary

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 monotherapy and combination therapy with ipilimumab in subjects with selected advanced solid tumors.

Conditions

Interventions

BIOLOGICAL

XmAb®23104

Monoclonal bispecific antibody

BIOLOGICAL

Yervoy® (ipilimumab)

Monoclonal antibody

Sponsors & Collaborators

  • ICON plc

    collaborator INDUSTRY

  • Xencor, Inc.

    lead INDUSTRY

Principal Investigators

  • Chet Bohac, MD, MSc · Xencor, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2024-02-15
Completion
2024-02-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03752398 on ClinicalTrials.gov